L3VLUP
ProSign in

ERAS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ERASVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ERAS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterERASVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20211 holders, $8.7m35 holders, $10.1bn
Q4 20211 holders, $6.4m28 holders, $12.4bn
Q1 20221 holders, $3.9m23 holders, $16.1bn
Q2 20221 holders, $2.0m25 holders, $18.1bn
Q3 2022none listed holders, n.a.22 holders, $18.4bn
Q4 20221 holders, $430k28 holders, $18.4bn
Q1 20231 holders, $496k26 holders, $21.4bn
Q2 20231 holders, $262k27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 20231 holders, $2.0m32 holders, $28.6bn
Q1 20241 holders, $1.8m31 holders, $29.8bn
Q2 20241 holders, $9.8m29 holders, $33.4bn
Q3 20241 holders, $11m27 holders, $33.5bn
Q4 20241 holders, $10m26 holders, $28.5bn
Q1 20251 holders, $5.7m21 holders, $35.4bn
Q2 2025none listed holders, n.a.21 holders, $32.3bn
Q3 2025none listed holders, n.a.22 holders, $25.9bn
Q4 20251 holders, $5.5m26 holders, $31.8bn
Q1 20266 holders, $211m25 holders, $31.8bn
Q2 20261 holders, $52m26 holders, $34.6bn
ERAS

Erasca Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
22
Reported value
$25.9bn
Buyers
13
Sellers
10

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 22 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ERAS (0)

None.

Only VRTX (22)

AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Freestone Grove Partners LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →